Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 2/20 | 0.54 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.54 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.54 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.53 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.53 |
| ▸ | ALPI | P09923 | 1/20 | 0.53 |
| ▸ | XIAP | P98170 | 1/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL599915 | 1.00 | SLC1A3 (0.54) | SLC1A3SLC1A2SLC1A1SLC7A5PKM | |
| SCHEMBL180118 | 1.00 | SLC1A3 (0.54) | SLC1A3SLC1A2SLC1A1SLC7A5PKM | |
| Trifluoroacetic Acid SCHEMBL4806415 | 0.91 | GRB2 (0.50) | SLC1A3SLC1A2SLC1A1SLC7A5PKM | |
| D-Glutamate SCHEMBL29008193 | 0.87 | SLC1A3 (0.50) | SLC1A3SLC1A2SLC1A1SLC7A5PKM | |
| SCHEMBL6248383 | 0.85 | ALOX5 (0.54) | SLC1A3SLC1A2SLC1A1ALOX5POLB | |
| SCHEMBL6248378 | 0.85 | ALOX5 (0.54) | SLC1A3SLC1A2SLC1A1ALOX5POLB | |
| SCHEMBL10305129 | 0.85 | ALOX5 (0.54) | SLC1A3SLC1A2SLC1A1ALOX5POLB | |
| SCHEMBL2265386 | 0.85 | SLC1A1 (0.59) | SLC1A3SLC1A2SLC1A1ALOX5 | |
| SCHEMBL9554473 | 0.84 | SLC7A5 (0.46) | SLC1A3SLC1A2SLC1A1SLC7A5PKM | |
| SCHEMBL12240912 | 0.84 | ALDH1A1 (0.50) | SLC1A3SLC1A2SLC1A1SLC7A5PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3178836-A1 | GADD45BETA TARGETING AGENTS | Imperial Innovations Limited (GB) | 2017-06-14 | — | — | EP | claimed |
| US-9434764-B2 | Skin care compositions and methods comprising selective agonists of melanocortin 1 receptor | UNIVERSITY OF CINCINNATI (US) | 2016-09-06 | — | — | US | claimed |
| US-20150368294-A1 | GADD45BETA TARGETING AGENTS | IP2IPO INNOVATIONS LIMITED (GB) | 2015-12-24 | — | — | US | claimed |
| US-20150299251-A1 | Skin Care Compositions and Methods Comprising Selective Agonists of Melanocortin 1 Receptor | UNIVERSITY OF CINCINNATI (US) | 2015-10-22 | — | — | US | claimed |
| US-20150297667-A1 | PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS OF USE COMPRISING SELECTIVE AGONISTS OF MELANOCORTIN 1 RECEPTOR | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-22 | — | — | US | claimed |
| EP-2925340-A2 | PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS OF USE COMPRISING SELECTIVE AGONISTS OF MELANOCORTIN 1 RECEPTOR | University Of Cincinnati (US) | 2015-10-07 | — | — | EP | claimed |
| EP-2922565-A2 | SKIN CARE COMPOSITIONS AND METHODS COMPRISING SELECTIVE AGONISTS OF MELANOCORTIN 1 RECEPTOR | University Of Cincinnati (US) | 2015-09-30 | — | — | EP | claimed |
| WO-2014081845-A2 | SKIN CARE COMPOSITIONS AND METHODS COMPRISING SELECTIVE AGONISTS OF MELANOCORTIN 1 RECEPTOR | UNIVERSITY OF CINCINNATI (US) | 2014-05-30 | — | — | WO | claimed |
| WO-2014081846-A2 | PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS OF USE COMPRISING SELECTIVE AGONISTS OF MELANOCORTIN 1 RECEPTOR | UNIVERSITY OF CINCINNATI (US) | 2014-05-30 | — | — | WO | claimed |
| US-20120277164-A1 | GADD45BETA TARGETING AGENTS | IMPERIAL INNOVATIONS LIMITED (GB) | 2012-11-01 | — | — | US | claimed |
| EP-2491051-A2 | GADD45BETA TARGETING AGENTS | Imperial Innovations Limited (GB) | 2012-08-29 | — | — | EP | claimed |
| WO-2011048390-A2 | GADD45BETA TARGETING AGENTS | IMPERIAL INNOVATIONS LIMITED (GB) | 2011-04-28 | — | — | WO | claimed |
| US-20250340574-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2025-11-06 | — | — | US | disclosed |
| EP-3650464-B1 | PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND | SHANGPHARMA INNOVATION INC (US) | 2025-11-05 | — | — | EP | disclosed |
| EP-4545553-A2 | PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND | ShangPharma Innovation Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| EP-4504739-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2025-02-12 | — | — | EP | disclosed |
| US-20100261769-A1 | Topical Compositions Comprising Non-Proteogenic Amino Acids and Methods of Treating Skin | AVON PRODUCTS, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-20080058383-A1 | Androgen Receptor Modulators | KARO BIO AB (SE) | 2008-03-06 | — | — | US | disclosed |
| EP-1685090-A1 | ANDROGEN RECEPTOR MODULATORS | KARO BIO AB (SE) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005042464-A1 | ANDROGEN RECEPTOR MODULATORS | KARO BIO AB (SE) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368294-A1 | GADD45BETA TARGETING AGENTS | DDB1, CCL2, DDIT3 | SLC1A3 3016/4885SLC1A2 3489/4885SLC1A1 3062/4885 |
| US-20250340574-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | SLC1A3 2879/4885SLC1A2 3321/4885SLC1A1 2485/4885 |
| US-20100261769-A1 | Topical Compositions Comprising Non-Proteogenic Amino Acids and Methods of Treating Skin | LOXL1, LOXL2, LOXL3 | SLC1A3 1600/4885SLC1A2 1798/4885SLC1A1 1511/4885 |
| US-20080058383-A1 | Androgen Receptor Modulators | NR5A1, ESRRA, AR | SLC1A3 2957/4885SLC1A2 2186/4885SLC1A1 2576/4885 |
| US-20120277164-A1 | GADD45BETA TARGETING AGENTS | DDB1, CCL2, DDIT3 | SLC1A3 3016/4885SLC1A2 3489/4885SLC1A1 3062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.